Condition
Non-small-cell Lung Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 12 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
12 shownClinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid TumoursNCT05698238 · 2024-01-01
NOT_YET_RECRUITINGPhase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKINCT05869162 · 2023-06-30
UNKNOWNOsimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.NCT04737382 · 2019-08-22
UNKNOWNStudy of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT03088540 · 2017-05-29
COMPLETEDThe Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence MonitoringNCT02647164 · 2016-01-01
UNKNOWNStudy of the Efficacy of SBRT on Unresectable Peripheral Primary TumorNCT02400424 · 2015-02-01
TERMINATEDCombination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung CancerNCT01799161 · 2014-12-01
WITHDRAWNAssessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung CancersNCT01421953 · 2011-08-01
COMPLETEDStudy Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)NCT00124280 · 2005-07-01
COMPLETEDA Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)NCT00126451 · 2004-12-01
TERMINATEDA Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT00091663 · 2004-08-01
COMPLETEDPET Imaging in Potentially Surgically Resectable Non-small Cell Lung CancersNCT00136890 · 2004-07-01
COMPLETEDCommon interventions
biopsyDIAGNOSTIC_TEST1CA9hu-1DRUG1CarboplatinDRUG1cemiplimabDRUG1CisplatinDRUG1CT-simulation and 4D PET-CTDEVICE1ctDAN analysisDIAGNOSTIC_TEST1Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cyclesDRUG1GemcitabineDRUG1gp96-Ig VaccineBIOLOGICAL1Immunologic EvaluationPROCEDURE1MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)DRUG1OxygenOTHER1PaclitaxelDRUG1PemetrexedDRUG1PET ImagingPROCEDURE1RAD001DRUG1SBRTRADIATION1SY-3505DRUG1Tarceva (erlotinib HCl)DRUG1TheophyllineDRUG1
Leading sponsors
Centre Leon Berard
1
Eckhard Podack
1
Genentech, Inc.
1
GenoSaber
1
Mabpro, a.s.
1
Merck Sharp & Dohme LLC
1
Novartis Pharmaceuticals
1
Ontario Clinical Oncology Group (OCOG)
1
Regeneron Pharmaceuticals
1
Shouyao Holdings (Beijing) Co. LTD
1
The Netherlands Cancer Institute
1
University Hospital, Bordeaux
1
Trial status mix
COMPLETED5
UNKNOWN3
TERMINATED2
NOT_YET_RECRUITING1
WITHDRAWN1
Phase mix
NA3
PHASE23
PHASE33
PHASE12
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.